CompletedInterventionalPhase 2Updated Dec 19, 2014
A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation | NCT01937663 | Trialant
CompletedInterventionalPhase 2Updated Nov 13, 2014
A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation
ClinicalTrials.gov ID
NCT01937663
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Last Update Posted
Nov 13, 2014Estimated
Primary Completion Date
Jan 2014Actual
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of tapered KWA-0711 dose in chronic constipation patients.
Chronic Constipation
KWA-0711
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
The patients who experienced fewer than three spontaneous bowel movements per week for more than 6 months prior to the enrollment.
The patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation
Exclusion Criteria:
Patients who have secondary constipation caused by systemic disorder.